SignalFDA/Bio
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
Reaching the 80th event advances the Phase 3 REGAL trial toward its primary analysis.
Context
What happened: SELLAS Life Sciences Group (NASDAQ: SLS) said its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached the pre-specified 80th event, triggering the final analysis.
Key numbers: 80th event (deaths) reached; topline primary endpoint results expected this quarter;
Why it matters: The company will proceed with database lock, unblinding, and statistical analysis of the primary endpoint. CEO Angelos Stergiou said positive results could position GPS as a first- and best-in-class novel immunotherapeutic option for AML patients in second complete remission.
Market: -1.1% today ($235.80), +1.3% YTD, 0.8x vol — as of 22:46 UTC
What changed
SELLAS Life Sciences Group (NASDAQ: SLS) said its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached the pre-specified 80th event, triggering the final analysis.
Why it matters
The company will proceed with database lock, unblinding, and statistical analysis of the primary endpoint. CEO Angelos Stergiou said positive results could position GPS as a first- and best-in-class novel immunotherapeutic option for AML patients in second complete remission.
Market: -1.1% today ($235.80), +1.3% YTD, 0.8x vol — as of 22:46 UTC